Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/medecine/biliary-disease/descriptif_3899981
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=3899981

Biliary Disease, Softcover reprint of the original 1st ed. 2017 From Science to Clinic

Langue : Anglais

Coordonnateurs : Hirschfield Gideon, Adams David, Liaskou Evaggelia

Couverture de l’ouvrage Biliary Disease
This book addresses the current understanding of the diagnosis and management of biliary disease across all ages, with emphasis on how the latest advances in clinical science may be integrated into current and future therapies. The coverage is wide ranging, encompassing congenital and acquired conditions including cholestatic syndromes, biliary atresia, drug-induced cholestasis, primary biliary cholangitis/cirrhosis, primary sclerosing cholangitis, cholangiocarcinoma, gallstone disease, and autoimmune sclerosing cholangitis. With contributions from basic and clinical scientists, the relevance of state-of-the-art mechanistic biology to diagnosis, treatment, and future opportunities for drug design is clearly explained. The balance between science and clinical practice will ensure that this book makes a lasting contribution to the field. A broad readership will find the book easy to access and a rich source of information on current best practice and evolving management strategies.
The clinical burden of biliary disease- a global perspective.- The healthy biliary tree- cellular and immunobiology.- Bile acid signalling and the current understanding of cholestasis: new opportunities for treatments?.- Animal models of biliary disease- current approaches and limitations.- The microbiome and human disease- a new organ of interest in biliary disease?.- Progressive familial intrahepatic cholestatic syndromes- genetic insights into biliary transporter function.- Biliary atresia- from pathology to treatment.- Drug induced cholestasis: mechanisms and importance.- Primary biliary cirrhosis- it’s science and practice.- Primary sclerosing cholangitis- current concepts in biology and strategies for new therapy.- Cholangiocarcinoma- evaluation of risk and new treatment paradigms.- Gallstone disease in the 21st century: practice and controversies.- Autoimmune sclerosing cholangitis/IgG4 cholangiopathy- new diseases?.- Conclusions and future opportunities.

David H. Adams, MD, FRCP, FMedSci is the Pro-Vice-Chancellor, Head of College of Medical and Dental Sciences and Dean of Medicine at the University of Birmingham, UK, as well as Professor of Hepatology and Honorary Consultant Hepatologist. He is an international leader in inflammatory liver disease and immune mechanisms of liver injury and has been at the forefront of developments in liver immunology over the last 20 years.  He has published more than 250 papers and has attracted significant grant income nationally and internationally. His clinical interests are transplant hepatology and autoimmune liver disease.  He has played major leadership roles nationally and internationally.  He has a particular interest in clinical academic careers and chairs the AMS Mentoring working group and has been a member of fellowship panels at MRC, Wellcome Trust and Core and INSERM (France). Laboratory research interests are focused on mechanisms of immune-mediated liverdisease. He was made a Fellow of the Academy of Medical Sciences in 2000 and an NIHR senior investigator in 2013.  He has a long-standing interest in understanding how leukocyte-endothelial interactions regulate the development and persistence of chronic inflammation and fibrosis in liver disease and how specific micro-environmental signals determine the positioning, activation and survival of effector cells within the liver. Based on this knowledge his laboratory demonstrated the role of specific adhesion molecules and chemokines in liver disease and helped to define the function of novel molecules including vascular adhesion protein-1.  His laboratory are now using their knowledge of the molecular mechanisms that regulate leukocyte trafficking to the liver to develop immune and cellular therapies for liver disease through the facilities provided by the Birmingham NIHR Liver BRU.

Gideon M. Hirschfield, MA, MB, BChir, FRCP, PhD is a Professor and Honorary Co

Presents concise, up-to-date information on diagnosis and management of biliary disease Explores in detail the relationship between science and clinical practice Covers the entire spectrum across adult and pediatric practice

Date de parution :

Ouvrage de 264 p.

15.5x23.5 cm

Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).

105,49 €

Ajouter au panier

Date de parution :

Ouvrage de 264 p.

15.5x23.5 cm

Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).

89,66 €

Ajouter au panier

Ces ouvrages sont susceptibles de vous intéresser